TransCode Therapeutics (NASDAQ: RNAZ) announced the initiation of a Phase 2a clinical trial evaluating its lead therapeutic candidate, TTX-MC138, in up to 45 colorectal cancer patients who remain circulating tumor DNA-positive following curative-intent therapy despite no radiographic evidence of disease, indicating minimal residual disease. Conducted in collaboration with Quantum Leap Healthcare Collaborative through its PRE-I-SPY clinical trial platform, the study will assess the biological and clinical activity of TTX-MC138 in reducing recurrence risk in this high-risk patient population.
TTX-MC138 is designed to target tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. This Phase 2a trial represents a significant step for TransCode as it seeks to address a critical unmet need in colorectal cancer: patients with minimal residual disease who are at high risk of recurrence. By focusing on this specific patient population, the trial could provide insights into the efficacy of TTX-MC138 in preventing disease progression.
The collaboration with Quantum Leap Healthcare Collaborative leverages the PRE-I-SPY platform, which is known for its adaptive trial design and ability to efficiently evaluate multiple therapies. This partnership may accelerate the development of TTX-MC138 and provide robust data on its potential benefits. The trial's outcome could have important implications for the treatment of minimal residual disease in colorectal cancer and potentially other cancers that overexpress microRNA-10b.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. The company's pipeline includes other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The initiation of this Phase 2a trial underscores TransCode's commitment to advancing novel therapies for patients with limited treatment options.
For more information about TransCode Therapeutics and its clinical programs, visit the company's newsroom at https://ibn.fm/RNAZ.
